EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access

Comparative effectiveness of sodium‐glucose cotransporter‐2 inhibitors versus glucagon‐like peptide‐1 receptor agonists in patients with type 2 diabetes and mild/moderate chronic kidney disease

Jinnie J Rhee iD, Jialin Han, Maria E Montez-Rath, Glenn M Chertow iD

Diabetes, Obesity and Metabolism · 2024-04 · 26 (4) · 1273-1281

DOI: 10.1111/dom.15427 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 08.01.2024. Verfasst von Jinnie J Rhee und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Stanford University School of Medicine, Stanford, California, USA. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Diabetes Mellitus, Type 2, Dipeptidyl-Peptidase IV Inhibitors, Myocardial Infarction. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim To determine the comparative effectiveness regarding major cardiovascular events of glucagon‐like peptide‐1 (GLP‐1) receptor agonists and sodium‐glucose cotransporter‐2 (SGLT‐2) inhibitors in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD). Materials and Methods We assembled a cohort of commercially insured adult patients with T2DM in the United States (derived from Optum Clinformatics DataMart 2003‐2021) who were new users of GLP‐1 receptor agonists or SGLT‐2 inhibitors. We compared risks of non‐fatal myocardial infarction or stroke in patients with and without CKD, and further categorized by CKD stage: stages G1 or G2 [estimated glomerular filtration rate (eGFR) ≥60 ml/min] and A2 (urine albumin to creatinine ratio 30 to

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular DiseasesDiabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsMyocardial InfarctionRenal Insufficiency, ChronicSodium-Glucose Transporter 2 InhibitorsStrokeHumansAlbuminsCreatinineGlucagon-Like Peptide-1 Receptor AgonistsGlucoseHypoglycemic AgentsSodiumUnited States

Stichwörter der Autor:innen

GLP-1SGLT-2 inhibitorantidiabetic drugcardiovascular diseasepharmacoepidemiologyreal-world evidence

Substanzen

AlbuminsCreatinineDipeptidyl-Peptidase IV InhibitorsGlucagon-Like Peptide-1 Receptor AgonistsGlucoseHypoglycemic AgentsSodiumSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Division of Nephrology, Stanford University School of Medicine, Stanford, California, USA.

ORCID-Profile: Jinnie J Rhee, Glenn M Chertow

Förderung

  • NIDDK NIH HHS
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Rhee, J. J., Han, J., Montez-Rath, M. E., & Chertow, G. M. (2024). Comparative effectiveness of sodium‐glucose cotransporter‐2 inhibitors versus glucagon‐like peptide‐1 receptor agonists in patients with type 2 diabetes and mild/moderate chronic kidney disease. Diabetes, Obesity and Metabolism, 26(4), 1273-1281. https://doi.org/10.1111/dom.15427

Vancouver

Rhee JJ, Han J, Montez-Rath ME, Chertow GM. Comparative effectiveness of sodium‐glucose cotransporter‐2 inhibitors versus glucagon‐like peptide‐1 receptor agonists in patients with type 2 diabetes and mild/moderate chronic kidney disease. Diabetes, Obesity and Metabolism. 2024;26(4):1273-1281. doi:10.1111/dom.15427

BibTeX
@article{Rhee2024,
  author = {Rhee, Jinnie J and Han, Jialin and Montez-Rath, Maria E and Chertow, Glenn M},
  title = {Comparative effectiveness of sodium‐glucose cotransporter‐2 inhibitors versus glucagon‐like peptide‐1 receptor agonists in patients with type 2 diabetes and mild/moderate chronic kidney disease},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2024},
  volume = {26},
  number = {4},
  pages = {1273--1281},
  doi = {10.1111/dom.15427}
}
Kostenlos starten →